Positive Interim R&D Results, Opening of New Laboratories, and Prestigious Awards Underline Growth Potential in Biotech Companies - Research Report on Gilead, Biogen Idec, Ariad, Incyte, and Sequenom

NEW YORK, July 1, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Incyte Corporation (NASDAQ: INCY), and Sequenom Inc. (NASDAQ: SQNM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On June 17, 2013, Gilead Sciences Inc. (Gilead) announced interim results from a single-arm, open-label Phase II study (Study 101-09) evaluating idelalisib (formerly GS-1101), which is an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Gilead reported that the single-agent treatment with idelalisib achieved an overall response rate of 53.6%, with median duration of response of 11.9 months at this interim analysis. "These data suggest that idelalisib has the potential to provide durable disease control to this group of patients who have few if any remaining conventional treatment options," said Gilles A. Salles, MD, PhD, Professor of Medicine, Department of Hematology, Claude Bernard University, Lyon-Sud Hospital Center, Pierre-Benite, France. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/9696_GILD]

--

Biogen Idec Inc. Research Report

On June 24, 2013, Biogen Idec Inc. (Biogen Idec) announced that it will release new data from a number of development and early-stage research programs at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held from June 29, 2013 to July 4, 2013 in Amsterdam, Netherlands. Biogen Idec reported that researchers will present 33 abstracts on clinical and pre-clinical research in hemophilia. Glenn Piece, M.D., Ph.D., Senior Vice President, Global Medical Affairs and Chief Medical Officer at Biogen Idec, stated, "The robust research being showcased at ISTH reflects our commitment to the community to address these unmet needs through innovative research and science. This includes striving to bring the first major advances in hemophilia treatment in more than fifteen years." The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/b35f_BIIB]

--

Ariad Pharmaceuticals Inc. Research Report

On June 18, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced that it has received two Gold Stevie Awards at the recently concluded 11th Annual American Business Awards in Chicago. Harvey J. Berger, M.D., Founder, Chairman and CEO of Ariad, commented, "The recognition of ARIAD through these two Stevie Awards at the same time represents the culmination of more than twenty years of dedication to ARIAD's vision -- to transform the lives of cancer patients with breakthrough medicines." Berger added, "All of our employees are to be commended for their contributions that led to ARIAD being named Company of the Year. Personally, I am humbled by the recognition as Pharmaceutical Executive of the Year by the American Business Awards." Ariad received the awards in the following categories: Company of the Year, Pharmaceuticals and Executive of the Year, Pharmaceuticals. The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/1015_ARIA]

--

Incyte Corporation Research Report

On June 13, 2013, Incyte Corporation (Incyte) and Eli Lilly and Company (Lilly) jointly announced the 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with active rheumatoid arthritis (RA). Incyte reported that baricitinib, formerly LY3009104 (INCB28050), is an orally available Janus kinase (JAK) inhibitor being studied for use in the treatment of certain autoimmune conditions, including RA. Peter Taylor, M.A., Ph.D., F.R.C.P., Norman Collisson Chair of Musculoskeletal Sciences in the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences at the University of Oxford, and steering Committee Member for the study, stated, "In this clinical trial baricitinib showed statistically and clinically significant improvements in the features of this condition, which were maintained throughout a year of treatment. To date, baricitinib has demonstrated an acceptable safety profile and side effects have generally been straightforward to manage. These encouraging findings support further investigation of this new drug in rheumatoid arthritis." The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/0762_INCY]

--

Sequenom Inc. Research Report

On June 12, 2013, Sequenom Inc. (Sequenom) announced that its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), has opened its new laboratory in Raleigh-Durham, North Carolina. Sequenom reported that the laboratory is now processing patient samples commercially. William Welch, President and COO of Sequenom, said, "We are excited about the opening in North Carolina of our third US-based laboratory location. Our investment in establishing this new presence on the East coast will allow us to better meet the needs of health care providers by providing critical additional capacity and geographic back-up needed to address the rapidly growing adoption of our testing services." The Full Research Report on Sequenom Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/d490_SQNM]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports